Medtronic, Inc. Release: European Economic Analysis Shows Cost Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) announced findings from an economic sub-study of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial published in the European Heart Journal demonstrating for the first time that cardiac resynchronization therapy (CRT) is cost-effective in mildly symptomatic heart failure (HF) patients.